Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans

Summary

Recently, the C-allele of polymorphism rs2359612 (VKORC1: c.283+837C>T) in the VKORC1 gene has been reported to represent a major risk factor for coronary heart disease (CHD), stroke, and aortic dissection in Chinese patients. VKOR activity itself is the rate-limiting step in gamma-carboxylation of vitamin K-dependent coagulation factors (factors II, VII, IX, X, protein C, S, and Z) and proteins of calcium metabolism (matrix Gla protein and osteocalcin). Gamma-carboxylation is essential for the biological activity of these proteins that have been previously hypothesised to play a role in the pathogenesis of atherosclerosis. It was the objective of this study to analyse the VKORC1 genotype frequency in patients with CHD and controls from Northern Germany and to investigate the association of VKORC1 and CHD risk in patients with an European background. CHD paients (n = 901) and healthy controls (n = 521) were part of the PopGen biobank. Case and control samples were matched for ethnic and geographic origin, age and gender. After typing German CHD patients and control individuals, no evidence for a statistically significant association was detected between VKORC1 genotype and CHD phenotype. Also stratification for gender and myocardial infarction yielded no significant results. In conclusion, the discrepant association findings in Chinese and German populations may be explained by ethnic differences in genetic and perhaps environmental predisposition, modifying the polygenic CHD phenotype by interacting withVKORC1 variants and thus conferring disease susceptibility in some populations, but not in others.

Keywords

Coronary heart disease - haplotype - rs9923231 - vitamin K - VKORC1

^* These authors contributed equally.

• References

• 1 Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
• 2 Stramba-Badiale M, Fox KM, Priori SG. et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27: 994-1005.
• 3 Stürmer T, Hasselbach P, Amelang M. Related personality, lifestyle, and risk of cardiovascular disease and cancer: follow-up of population based cohort. Br Med J 2006; 332: 1359.
• 4 Wang Y, Zhang W, Zhang Y. et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-1621.
• 5 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
• 6 Li T, Chang CY, Jin DY. et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-544.
• 7 Rost S, Fregin A, Hunerberg M. et al. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 2005; 94: 780-786.
• 8 Oldenburg J, Bevans CG, Muller CR. et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 2006; 8: 347-353.
• 9 Sconce EA, Khan TI, Wynne HA. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
• 10 Geisen C, Watzka M, Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
• 11 Yuan HY, Chen JJ, Lee MT. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
• 12 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
• 13 Sun YM, Jin DY, Camire RM. et al. Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood 2005; 106: 3811-3815.
• 14 Hallgren KW, Qian W, Yakubenko AV. et al. r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step. Biochemistry 2006; 45: 5587-5598.
• 15 Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-2132.
• 16 Levy RJ, Gundberg C, Scheinman R. The identification of the vitamin K-dependent bone protein osteocalcin as one of the gamma-carboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983; 46: 49-56.
• 17 Luo G, Ducy P, McKee MD. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
• 18 Herrmann SM, Whatling C, Brand E. et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2386-2393.
• 19 O'donnell CJ, Shea MK, Price PA. et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification.Arterioscler Thromb Vasc Biol. 2006 doi:10.1161/01.ATV.0000245793.83158.06.
• 20 Krawczak M, Nikolaus S, von Eberstein H. et al. PopGen: Population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet 2006; 9: 55-61.
• 21 El Mokhtari NE, Ott SJ, Nebel A. et al. A functional variant in the CARD4 gene and risk of premature coronary heart disease. Int J Immunogenet 2006; 33: 307-311.
• 22 Hampe J, Wollstein A, Lu T. et al. An integrated database for Taqman based high throughput SNP genotyping. Bioinformatics 2001; 17: 654-655.
• 23 Barrett JC, Fry B, Maller J. et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
• 24 Lowe GD. Venous and arterial thrombosis: epidemiology and risk factors at various ages. Maturitas 2004; 47: 259-263.
• 25 Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005; 39: 667-679.
• 26 Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med 2006; 259: 493-519.
• 27 Weiner P, Waizman J, Weiner M. et al. Smoking and first acute myocardial infarction: age, mortality and smoking cessation rate. Isr Med Assoc J 2000; 2: 446-449.
• 28 Emberson JR, Whincup PH, Morris RW. et al. Lifestyle and cardiovascular disease in middle-aged British men: the effect of adjusting for within-person variation. Eur Heart J 2005; 26: 1774-1782.
• 29 Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 2000; 64: S27-47.
• 30 Watkins H, Farrell M. Genetic susceptibility to coronary artery disease: from promise to progress. Nature Genetics Reviews 2006; 7: 163-173.
• 31 Wang Y, Zhen Y, Shi Y. et al. Vitamin k epoxide reductase: a protein involved in angiogenesis. Mol Cancer Res 2005; 3: 317-323.
• 32 Yan L, Zhou B, Greenberg D. et al. Vitamin K status of older individuals in northern China is superior to that of older individuals in the UK. Br J Nutr 2004; 92: 939-945.
• 33 Beavan SR, Prentice A, Stirling DM. et al. Ethnic differences in osteocalcin gamma-carboxylation, plasma phylloquinone (vitamin K1) and apolipoprotein E genotype. Eur J Clin Nutr 2005; 59: 72-81.
• 34 Geleijnse JM, Vermeer C, Grobbee DE. et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004; 134: 3100-3105.
• 35 Spronk HM, Soute BA, Schurgers LJ. et al. Tissuespecific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40: 531-537.